| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P6179 | Dimensions Publication ID | 1001247019 |
| P356 | DOI | 10.2165/00003088-200241110-00004 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.2165/00003088-200241110-00004 |
| P698 | PubMed publication ID | 12190332 |
| P5875 | ResearchGate publication ID | 11198023 |
| P2093 | author name string | Sven Ulrich | |
| Jürgen Läuter | |||
| P2860 | cites work | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| The number needed to treat: a clinically useful measure of treatment effect | Q29619672 | ||
| Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials | Q31827980 | ||
| Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: a therapeutic window relationship | Q32068069 | ||
| Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials | Q33758954 | ||
| Validity of clinical trials of antidepressants | Q33852811 | ||
| Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness | Q37339065 | ||
| Therapeutic monitoring of antidepressant drugs: guidelines updated | Q38718650 | ||
| Interaction between amitriptyline and phenothiazine in man: Effect on plasma concentration of amitriptyline and its metabolite nortriptyline and the correlation with clinical response | Q39289745 | ||
| Amitriptyline plasma-concentration and clinical effect. A World Health Organisation Collaborative Study | Q39471857 | ||
| Plasma tricyclic drug levels in amitriptyline-treated depressed patients | Q39685519 | ||
| The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis | Q39693656 | ||
| Therapeutic drug monitoring. Principles and practice | Q40866461 | ||
| A clinical trial comparing sustained release amitriptyline (Saroten® Retard) and conventional amitriptyline tablets (Saroten®) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortriptyline | Q40917973 | ||
| Meta-analysis: a method for synthesizing research | Q40927786 | ||
| Amitriptyline Nortriptyline Plasma Levels and Therapeutic Response in Depressed Women | Q40948630 | ||
| Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline | Q40977539 | ||
| Pharmacokinetics and pharmacodynamics of amitriptyline in depression | Q41213838 | ||
| The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia | Q41734960 | ||
| Profound behavioral toxicity due to tricyclic antidepressants. | Q42222314 | ||
| A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade | Q43738505 | ||
| Levels of amitriptyline and its metabolites in the treatment of depression | Q43873437 | ||
| Behavioral and cognitive toxicity related to elevated plasma tricyclic antidepressant levels | Q44327281 | ||
| Radioimmunoassay of Amitriptyline and Nortriptyline in Body Fluids | Q44483583 | ||
| A comparison study of amitriptyline and nortriptyline with plasma levels | Q45215870 | ||
| Amitriptyline plasma levels and clinical response in primary depression: II | Q45239964 | ||
| The Antidepressant Web: Marketing depression and making medicines work | Q46937506 | ||
| Sample size calculations for clinical pharmacology studies | Q47209592 | ||
| Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. | Q51018829 | ||
| Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. | Q51986852 | ||
| Plasma levels, psychophysiological variables, and clinical response to amitriptyline. | Q52288682 | ||
| Antidepressive effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. | Q52877703 | ||
| Antidepressant treatment of children: clinical relapse is unrelated to tricyclic plasma concentrations. | Q53852057 | ||
| Relationship between plasma level and therapeutic effect of nortriptyline. | Q55365453 | ||
| Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs: Meta-regression analysis | Q60621652 | ||
| Amitriptyline plasma concentration and clinical response | Q66904585 | ||
| Determination of amitriptyline at nanogram levels in serum by electron capture gas-liquid chromatography | Q66964782 | ||
| Amitriptyline dosage schedule, sampling time and tricyclic plasma levels | Q67692121 | ||
| Serum concentrations of amitriptyline and its metabolites and clinical effect in depressive patients | Q67981485 | ||
| [Relation of plasma levels and clinical response to amitriptyline in treating endogenous depression] | Q68046683 | ||
| Aspects of amitriptyline and nortriptyline plasma levels monitoring in depression | Q68732524 | ||
| Imipramine and amitriptyline plasma concentrations and clinical response in major depression | Q68864253 | ||
| Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin | Q68994545 | ||
| [Plasma amitriptyline levels and its therapeutic effect in endogenous depression] | Q69432300 | ||
| Validation of a therapeutic plasma level range in amitriptyline treatment of depression | Q69613526 | ||
| [Relation of plasma amitriptyline and nortriptyline levels to the therapeutic response in endogenous depression] | Q69687780 | ||
| Selection of neuroleptic dosage | Q69863959 | ||
| Tricyclic antidepressants--blood level measurements and clinical outcome: an APA Task Force report. Task Force on the Use of Laboratory Tests in Psychiatry | Q69882600 | ||
| Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients | Q70090501 | ||
| Pharmacokinetics and efficacy of maprotiline and amitriptyline in endogenous depression: a double-blind controlled trial | Q70174894 | ||
| Monitoring of tricyclic antidepressant therapy | Q70307401 | ||
| Tricyclic plasma levels in depressed outpatients treated with amitriptyline | Q70439073 | ||
| Studies in the classification of affective disorders. The relationship between anxiety states and depressive illnesses. II | Q70479385 | ||
| Zimelidine and amitriptyline in the treatment of depressive illness in general practice | Q70544945 | ||
| Serum levels and response to amitriptyline in depressed out-patients | Q70720629 | ||
| Amitriptyline and nortriptyline plasma levels monitoring. Perspective in clinical practice | Q70904670 | ||
| Amitriptyline levels and clinical effects | Q71080084 | ||
| Plasma levels and clinical improvement--a comparative study of clomipramine and amitriptyline in depression | Q71249747 | ||
| Amitriptyline, nortriptyline plasma levels and clinical response in women with affective disorders | Q71250221 | ||
| On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients | Q71250224 | ||
| Amitriptyline metabolism in relation to antidepressive effect | Q71295463 | ||
| Amoxapine and amitriptyline: serum levels and clinical response in patients with primary unipolar depression | Q71439682 | ||
| Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels | Q71611837 | ||
| Amitriptyline and nortriptyline response profiles in unipolar depressed patients | Q71621683 | ||
| Clinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patients | Q71939161 | ||
| A double-blind comparison of dothiepin and amitriptyline in patients with primary affective disorder: serum levels and clinical response | Q72132252 | ||
| Monitoring tricyclic antidepressant concentrations in serum by fluorescence polarization immunoassay compared with gas chromatography and HPLC | Q72193449 | ||
| Amitriptyline: looking through the therapeutic window | Q72573574 | ||
| Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients | Q72579358 | ||
| Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response | Q72810727 | ||
| Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state | Q73169233 | ||
| [The use of low-dose amitriptyline in psychogeriatrics. A clinical, pharmacokinetic and pharmacogenetic study] | Q93601298 | ||
| Plasma concentration of amitriptyline and clinical response | Q93723513 | ||
| Plasma concentration of nortriptyline and clinical response in depressive illness | Q93729256 | ||
| CLINICAL TRIAL OF THE TREATMENT OF DEPRESSIVE ILLNESS. REPORT TO THE MEDICAL RESEARCH COUNCIL BY ITS CLINICAL PSYCHIATRY COMMITTEE | Q93962452 | ||
| P433 | issue | 11 | |
| P921 | main subject | amitriptyline | Q58397 |
| P304 | page(s) | 853-876 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression | |
| P478 | volume | 41 |
| Q91670665 | Drug metabolism in drug discovery and development |
| Q85743756 | Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions |
| Q37806757 | Gender differences in antidepressant drug response |
| Q36114397 | Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review |
| Q37956206 | Pharmacogenetics in psychiatry: translating research into clinical practice. |
| Q46298114 | Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers |
| Q36419988 | Role of pharmacologically active metabolites in drug discovery and development |
| Q35236618 | The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. |
| Q35956204 | The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. |
| Q38154910 | The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy |
| Q36582619 | Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance |
| Q37111340 | Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? |
| Q57244669 | Therapeutic drug monitoring of antidepressant and antipsychotic drugs |
| Q46914406 | Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. |
Search more.